MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position
MacroGenics reported Q2 revenue of $32.8 million, up from $6.9 million a year ago, driven by a $24.5 million milestone payment from Sanofi. The company completed the sale of its manufacturing operations to Bora for $119.6 million, transitioning to a fully outsourced model and targeting a workforce reduction to approximately 140 employees.
Key figures
- Eps
- 0.31
- Revenue
- $32.8 million
- Guidance
- cash runway through 2028
- Operating loss
- $13.9 million
- Pro forma cash
- $327 million
- Shares outstanding
- 63645711
- Asset sale proceeds
- $119.6 million
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.